We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in the coming years.
Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.
For thousands of years, the schisandra berry has been used to preserve vital energy, as well as support kidney, lung, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results